Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus gemcitabine and cisplatin for locally recurrent nasopharyngeal carcinoma
ChiCTR2000035200Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Objective response rate. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
sintilimabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2000035200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035200.